ABSTRACT
OBJECTIVE: To evaluate the effect of different surgical techniques on primary stability, particularly in poor-quality bone with or without a crestal cortical bone. MATERIALS AND METHODS: Three implant site preparation techniques-undersized drilling (UD), undersized drilling and coronal widening with a cortical drill (UD + CD), undersized drilling and coronal tapping with a cortical tap (UD + CT)-were compared in 2 different low-density polyurethane bone models either with or without the crestal cortical bone. Insertion torque values (ITVs) for each technique was recorded. RESULTS: Statistically significant difference was observed for all 3 surgical techniques. In the presence of a crestal cortical bone, the peak ITV for UD was the highest, UD + CT the second, and UD + CD the lowest. All peak ITVs remained significantly lower in the absence of a crestal cortical bone. CONCLUSION: Our findings suggested that UD + CTmay be the most effective implant surgical technique to achieve an ideal primary stability in low-density bone with a thin crestal cortical bone layer. Also, this technique may prevent compression necrosis of the dense cortical bone.
Subject(s)
Alveolar Process/surgery , Dental Implantation, Endosseous/instrumentation , Alveolar Bone Loss/pathology , Alveolar Bone Loss/surgery , Alveolar Process/pathology , Dental Implantation, Endosseous/methods , Dental Implants , HumansABSTRACT
Multifunctional mesoporous silica nanocomposites are attractive carriers for targeted drug delivery in nanomedicine. Although promising developments have been made in the fabrication of multifunctional mesoporous silica nanocomposites, the design and mass production of novel multifunctional carriers are still challenging. This paper reports the facile one-pot fabrication of a multifunctional inorganic composite composed of superparamagnetic Fe3O4 nanoparticles and coated dye-functionalized mesoporous silica with a high specific surface area. The resulting composite particles had a tunable particle size, special open pore channels with high specific surface area, which is quite favorable for drug loading and release properties, as well as luminescent and superparamagnetic properties suitable for targeted drug delivery and tracking. This composite exhibited low toxicity, suggesting potential biomedical applications.
Subject(s)
Biomedical Technology/methods , Nanofibers/chemistry , Silicon Dioxide/chemistry , Animals , Cell Death/drug effects , Endocytosis/drug effects , Ferric Compounds/chemistry , Fibroblasts/cytology , Fibroblasts/drug effects , Magnetic Phenomena , Mice , Microscopy, Fluorescence , Nanofibers/toxicity , Nanofibers/ultrastructure , Particle Size , Porosity , Silicon Dioxide/toxicity , Spectrometry, FluorescenceABSTRACT
This study concentrates on the potential application of conjugated polyelectrolytes (CPEs) to cell imaging and DNA delivery. Four different types of polyfluorene copolymers, namely, PAHFP-Br, PAEFP-Br, PAHFbT-Br, and PSBFP-Na, which have the same π-conjugated backbone but different side chains, were synthesized. For cytotoxicity testing, L-929 fibroblastic cells were treated with increasing concentrations (0-50 µM) of each CPE and then cell viability was determined by WST-8 assay. Cellular uptake of CPEs into cultured L-929 cells was observed by fluorescence microscopy. To examine DNA delivery by CPEs, the cells were incubated for 1 H with PAHFP-Br/fluorescein (Fl)-labeled single-stranded DNA (ssDNA-Fl) complex and then visualized by fluorescence microscopy. Cytotoxicity of CPEs was increased in a dose-dependent manner but at lower than 10 µM, PAHFP-Br, PAEFP-Br, and PSBFP-Na did not show any cytotoxic effects on the cells. When added to cell cultures at 1 µM, PAHFP-Br/ssDNA-Fl complex was delivered and then dissociated into PAHFP-Br and ssDNA-Fl within the cells. This result implies that PAHFP-Br can enable cell imaging and DNA delivery into fibroblastic cells. Therefore, it is suggested that PAHFP-Br with various advantages such as low cytotoxicity and high fluorescence efficiency can be extensively used as a potential agent for cell imaging and gene delivery.
Subject(s)
DNA/chemistry , DNA/metabolism , Drug Carriers/chemistry , Fibroblasts/cytology , Fibroblasts/metabolism , Gene Transfer Techniques , Molecular Imaging/methods , Polymers/chemistry , Animals , Biological Transport , Cell Line , Cell Survival/drug effects , DNA/genetics , Drug Carriers/metabolism , Drug Carriers/toxicity , Fluorenes/chemistry , Mice , Optical Phenomena , Polymers/metabolism , Polymers/toxicityABSTRACT
Safe and stable cryopreservation is critical for research involving human embryonic stem cells (hESCs). Dimethyl sulfoxide (DMSO) is a popular cryoprotective agent; however, its cytotoxicity cannot be ignored. Thus, there is a need for an alternate cryoprotectant. We reported previously that a novel cryopreservation reagent, StemCell Keep™ (SCK), was effective for cryopreserving human induced pluripotent stem cells (hiPSCs) by vitrification. Because hESCs and hiPSCs are not identical, the current study examined the use of SCK on hESCs. hESCs cryopreserved with SCK were thawed and cultured on SNL 76/7 cells, which were derived from a mouse fibroblast STO cell line transformed with neomycin resistance and murine LIF genes. After cryopreservation, cultured hESCs were assessed for their attachment ability and characterized by alkaline phosphatase (AP) and immunocytochemical (ICC) staining, fluorescence-activated cell sorting (FACS), reverse transcription polymerase chain reaction (RT-PCR), and karyotyping. The proliferation of SCK-cryopreserved hESCs cultured on SNL cells, or in feeder-free conditions, was higher than that of cells preserved in a solution of 2 M DMSO, 1 M acetamide, and 3 M propylene glycol (DAP). The cell number with SCK-cryopreserved hESCs was about twice that of hESCs cryopreserved in DAP. The pluripotency of SCK-cryopreserved hESCs was similar to that of DAP-cryopreserved hESCs based on AP staining. Data from ICC, FACS, and RT-PCR analyses showed that stem cell markers were continually expressed on SCK-cryopreserved hESCs. The teratoma assay showed that SCK-cryopreserved hESCs differentiated into three germ layers. Furthermore, SCK-cryopreserved hESCs had normal karyotypes. These data indicate that SCK was effective for cryopreservation of hESCs by vitrification.
Subject(s)
Cryopreservation/methods , Cryoprotective Agents/pharmacology , Embryonic Stem Cells/drug effects , Vitrification/drug effects , Acetamides/pharmacology , Buffers , Cell Culture Techniques/methods , Cell Proliferation/drug effects , Cryoprotective Agents/chemistry , Dimethyl Sulfoxide/pharmacology , Embryonic Stem Cells/cytology , Flow Cytometry , Humans , Karyotyping , Propylene Glycol/pharmacology , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
BACKGROUND: Mechanical properties and cyto-compatibility of a composite scaffold which possessed negative (-) Poisson's ratio (NPR) was investigated for effective load transfer from auxetic scaffold to cell. METHODS: Organic/inorganic composite scaffolds were prepared by mixing hydroxyapatite (HA) to poly(lactide-co-glycolide) (PLGA). To induce NPR in composite scaffold, 3-directional volumetric compression was applied during the scaffold fabrication at adequate temperature(60°C). The pore size of scaffold ranged between 355-400 µm. RESULTS: Poisson's ratios of NPR scaffolds and control scaffolds were -0.07 and 0.16 at 10 % strain. For stable physical stimulating to loaded cells, ceramic/polymer composite scaffold was prepared by incorporating HA in PLGA to increase mechanical strength. Compressive strength of the HA/PLGA composite scaffold (15 wt. % HA to PLGA) was about 21.7 % higher than that of PLGA-only scaffold. The recovery rates of the NPR composite scaffold after applying compression in the dry and wet states were 90 % and 60 %, respectively. Also the composite scaffold was shown to have better hydrophilicity (61.9°) compared to the PLGA-only scaffolds (65.3°). Cell proliferation of osteoblast-like cell line (MG-63) in the composite scaffold was 20 % higher than in PLGA-only scaffold at static compressive stimulation. For dynamic compressive stimulation (15 min cyclic interval), cell proliferation in the composite scaffold was 2 times higher than that of in PLGA-only scaffold. In conclusion, NPR composite (HA/PLGA) scaffold was effective in isotropic compressive load delivery for osteogenic cell proliferation. CONCLUSION: This composite scaffold with stimulation can be used as tissue engineered scaffold and dynamic cell culture system for bone tissue regeneration.
ABSTRACT
BACKGROUND: Auxetic scaffolds (experimental) was fabricated by using poly(D, L-lactic-co-glycolic acid), 50:50, (PLGA) for effective bone cell proliferation with mechanical stimulation. METHODS: Negative Poisson's ratio in scaffold, 3-directional volumetric compression was applied during the scaffold fabrication at adequate temperature (60 °C). The pore size of scaffold ranged between 355 and 400 µm. RESULTS: The porous morphology of the prepared auxetic scaffolds had shown partially concave and dent shapes in SEM image as expected. The lowest Poisson's ratios of experimental group was -0.07 at 60 °C/10 min. Compressive strength of experimental group was shown about 3.12 times higher than control group (conventional scaffold) in dry state at 25 °C. The compressive strengths of both groups were tended to be decreased dramatically in wet state compared to in dry state. However, compressive strengths of experimental group were higher 3.08 times and 1.88 times in EtOH/PBS (25 °C) and EtOH/PBS/DMEM (37 °C) than control group in wet state, respectively. Degradation rate of the scaffolds showed about 16 % weight loss in 5 weeks. In cell attachment test, experimental group showed 1.46 times higher cell proliferation than control group at 1-day with compressive stimulation. In 3-day culture, the experimental group showed 1.32 times higher than control group. However, there was no significant difference in cell proliferation in 5-day cultivation. CONCLUSION: Overall, negative Poisson's ratio scaffolds with static mechanical stimulation could affect the cell proliferation at initial cultivation time.
ABSTRACT
During the last few decades, considerable research on diabetic wound healing strategies has been performed, but complete diabetic wound healing remains an unsolved problem, which constitutes an enormous biomedical burden. Herein, hyaluronic acid (HA)/poly(lactic-co-glycolic acid, PLGA) core/shell fiber matrices loaded with epigallocatechin-3-O-gallate (EGCG) (HA/PLGA-E) are fabricated by coaxial electrospinning. HA/PLGA-E core/shell fiber matrices are composed of randomly-oriented sub-micrometer fibers and have a 3D porous network structure. EGCG is uniformly dispersed in the shell and sustainedly released from the matrices in a stepwise manner by controlled diffusion and PLGA degradation over four weeks. EGCG does not adversely affect the thermomechanical properties of HA/PLGA-E matrices. The number of human dermal fibroblasts attached on HA/PLGA-E matrices is appreciably higher than that on HA/PLGA counterparts, while their proliferation is steadily retained on HA/PLGA-E matrices. The wound healing activity of HA/PLGA-E matrices is evaluated in streptozotocin-induced diabetic rats. After two weeks of surgical treatment, the wound areas are significantly reduced by the coverage with HA/PLGA-E matrices resulting from enhanced re-epithelialization/neovascularization and increased collagen deposition, compared with no treatment or HA/PLGA. In conclusion, the HA/PLGA-E matrices can be potentially exploited to craft strategies for the acceleration of diabetic wound healing and skin regeneration.
Subject(s)
Catechin/analogs & derivatives , Diabetes Mellitus, Experimental/drug therapy , Hyaluronic Acid/administration & dosage , Hyaluronic Acid/chemistry , Polyglycolic Acid/chemistry , Wound Healing/drug effects , Animals , Catechin/administration & dosage , Catechin/chemistry , Collagen/metabolism , Fibroblasts/drug effects , Neovascularization, Physiologic/drug effects , Polyglycolic Acid/administration & dosage , Rats , Rats, Sprague-Dawley , Skin/drug effectsABSTRACT
Considering the various pharmacological activities of epigallocatechin-3-O-gallate (EGCG) including anticancer, and anti-inflammatory, antidiabetic, and so forth, relatively less attention has been paid to the antiaging effect of EGCG on primary cells. In this study, the preventive effects of EGCG against serial passage-induced senescence were investigated in primary cells including rat vascular smooth muscle cells (RVSMCs), human dermal fibroblasts (HDFs), and human articular chondrocytes (HACs). The involvement of Sirt1 and acetylated p53 was examined as an underlying mechanism for the senescence preventive activity of EGCG in HDFs. All cells were employed with the initial passage number (PN) between 3 and 7. For inducing senescence, the cells were serially passaged at the predetermined times and intervals in the absence or presence of EGCG (50 or 100 µM). Serial passage-induced senescence in RVSMCs and HACs was able to be significantly prevented at 50 µM EGCG, while in HDFs, 100 µM EGCG could significantly prevent senescence and recover their cell cycle progression close to the normal level. Furthermore, EGCG was found to prevent serial passage- and H(2)O(2)-induced senescence in HDFs by suppressing p53 acetylation, but the Sirt1 activity was unaffected. In addition, proliferating HDFs showed similar cellular uptake of FITC-conjugated EGCG into the cytoplasm with their senescent counterparts but different nuclear translocation of it from them, which would partly account for the differential responses to EGCG in proliferating versus senescent cells. Taking these results into consideration, it is suggested that EGCG may be exploited to craft strategies for the development of an antiaging or age-delaying agent.
Subject(s)
Catechin/analogs & derivatives , Cellular Senescence/drug effects , Cytoprotection/drug effects , Dermis/cytology , Fibroblasts/cytology , Protective Agents/pharmacology , Tumor Suppressor Protein p53/metabolism , Acetylation/drug effects , Animals , Catechin/pharmacology , Cell Cycle/drug effects , Cell Death/drug effects , Cell Proliferation/drug effects , Cells, Cultured , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Fibroblasts/drug effects , Fibroblasts/metabolism , Fluorescein-5-isothiocyanate/metabolism , Humans , Hydrogen Peroxide/pharmacology , Inhibitory Concentration 50 , Microscopy, Fluorescence , Rats , Sirtuin 1/metabolism , beta-Galactosidase/metabolismABSTRACT
Localized drug delivery from drug-eluting stents has been accepted as one of the most promising treatment methods for preventing restenosis after stenting. However, hypersensitivity reactions caused by their nonresorbable polymer coatings and bare-metal stents may result in serious clinical sequelae. Epigallocatechin-3-O-gallate (EGCG), the predominant catechin from tea, has been shown to exert anti-thrombotic, anti-inflammatory and anti-proliferative activities. In this study, it was hypothesized that sustainedly released EGCG from biodegradable poly(lactide-co-epsilon-caprolactone, PLCL) would suppress the proliferation of vascular smooth muscle cells (VSMCs). EGCG-releasing PLCL (E-PLCL) was prepared by blending PLCL with EGCG. The surface morphology, roughness and melting temperature of PLCL were not changed despite EGCG addition. EGCG was uniformly dispersed into E-PLCL and sustainedly released for periods up to 7 days by controlled diffusion rather than PLCL degradation. Moreover, EGCG did not affect tensile strength at break, but significantly increased the elastic modulus of PLCL. The proliferation of VSMCs onto E-PLCL was significantly suppressed although the cell attachment onto E-PLCL had been higher than that onto PLCL. On the other hand, EGCG-eluting polymeric stents were prepared with neither cracks nor webbings between struts, and their structural integrity was maintained without delamination or destruction. These results suggest that E-PLCL can be potentially applied for fabricating an EGCG-eluting vascular stent, namely an EGCG-eluting polymeric stent, or even an EGCG-releasing polymer-coated metal stent, to prevent thrombosis, inflammation and in-stent restenosis.